Medical Professional Liability Association’s Post

We are so happy to announce that our first article on our PT DOAC reagent has been published! This milestone represents a significant step forward in our research efforts and demonstrates our commitment to advancing scientific knowledge in the field. Read the full article here! Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban. https://rdcu.be/dz7tC

🚩 Biosimilars: A Landscape of Innovation and Regulatory Nuances 🎯 Biosimilars are a rapidly growing class of medications offering a promising future for healthcare accessibility and affordability. 👀 But navigating the world of biosimilars requires understanding not only their therapeutic value but also the subtle differences in regulatory frameworks across jurisdictions. 💯 This article prepared by my colleague Anahit Grigoryan and myself, delves into the world of biosimilars, exploring their definition, indications, cost benefits, and the exciting possibilities for future advancements. ✅️ Join the Conversation! Share your thoughts on the future of biosimilars and the role of research in driving innovation. Let's work together to ensure biosimilars reach their full potential in improving patient lives worldwide. please find below article's link: https://lnkd.in/eijYKJ77

Labb Offers "REAL" Innovation Again (And No, We’re Not Talking About Wider Test Strip Nonsense or Fancy Stickers)! In Q1, we’re dropping the most advanced rapid drug test the world’s ever seen. We’re talking billions—wait, actually trillions—of panel configurations across 50+ drugs and hundreds of metabolites. Want to run a 50-panel rapid drug screen? Go for it. Good luck finding a lab that can confirm all 50! The all-new Labb DRT blows past the average lab menu, taking drug testing to a whole new level. Need to test for bath salts or psychedelics? No problem. Just slap on our patent-pending expansion panel, and voilà, even more detection at your fingertips. Curious about the full menu? Spoiler: it’s already live. The guide we released weeks ago is actually our new drug test menu. Check it out at Labb.com/guidebook. The all-new Labb DRT isn’t just a "flexible cup"—this is total drug coverage on a digital level and not blind faith rapid. You're welcome!

New research enhances the potential safety and programmability of universal CAR T-cells, a breakthrough in engineered #TcellTherapies. The findings not only boost therapeutic precision but also opens doors for enhanced safety measures. Read the published research in ACS Publications here: https://ow.ly/Ft0c50QoLc7 #CARTcells #PrecisionMedicine

Flubromazolam has been studied in the living, but there were no published reports including measured drug concentrations in post-mortem cases. Therefore, this study was published: Flubromazolam: detection in five post-mortem cases. Abdul K, Hikin LJ, Smith P, Kurimbokus H, Ashong E, Couchman L, Morley SR. This publication reported on five cases in which flubromazolam was detected in a systematic screen using high-resolution mass spectrometry and then quantified in femoral blood. 📄 Read the study: https://ow.ly/1o5N50PSPmN #academicresearch #drugdiscovery #drugresearch #druglegislation #healthresearch

𝐈𝐬 𝐭𝐡𝐞 𝐄𝐔 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐅𝐫𝐚𝐦𝐞𝐰𝐨𝐫𝐤 𝐚 𝐂𝐚𝐭𝐚𝐥𝐲𝐬𝐭 𝐟𝐨𝐫 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐨𝐫 𝐚 𝐁𝐚𝐫𝐫𝐢𝐞𝐫 𝐭𝐨 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐜𝐜𝐞𝐬𝐬? Ludovic, CEO of THERYQ, shares his thoughts on the topic during LSI Europe 24 #QARA #MDR #Medicaldevice #Regulation

By May 2024 labs must declare publicly that their in-house tests meet the GSPRs. Watch the latest IVDReady webinar online to learn more. Watch the webinar: https://lnkd.in/dHXqbFEP Our recent webinar illuminates the basics of the 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝗦𝗮𝗳𝗲𝘁𝘆 𝗮𝗻𝗱 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀, which labs were to have fulfilled by May 2022. By May 2024 labs must take active steps to demonstrate fulfilment of GSPRs, including a public declaration that their in-house tests meet the requirements. This webinar explains it all, including how standards can be applied to reliably fulfil GSPRs. Special guest Prof. Kurt Zatloukal from the Diagnostic and Research Center for Molecular Biomedicine at the Medizinische Universität Graz outlines a prime example of how GSPRs and standards can lead to better diagnostics. #IVDR #IVDReady #regulatory #laboratories

And here is someone who is paving the future of #precisionmedicine: Virginia Savova, Ph. D. Savova talks about medicine with cellular precision and the value of single-cell data in drug development at #TriCon Precision Medicine!

Watch Dr. Rajamannar Thennati discuss his oral session Multiple Ascending Dose of the Novel GLP-1RA Utreglutide in Individuals With Obesity-A Phase I Study at #OW2024. Comment below on what you want to learn from this session!

white paper, 'CDx Market Access: The Path to Precision Medicine Success,' provides insights based on real-world experiences. Gain a competitive edge taking your precision medicine to market. Download the white paper today: https://lnkd.in/gEr5fTzJ #CDx #CompanionDiagnostics #PrecisionMedicine